Real-World Experience with Dolutegravir-Based Two-Drug Regimens

Table 3

Reasons for discontinuation among patients who discontinued DTG 2DR during the study period.

	N = 278
Patients discontinuing DTG 2DR, n (%)	15 (5.4)
Time to discontinuation of DTG 2DR, years, mean (SD)	2.9 (1.2)
Reasons for discontinuation of DTG 2DR, n (%)	N = 15
Virologic failure	4 (26.7)
Toxicity/intolerance of ARVs	3 (20.0)
Simplification/streamlining of treatment	3 (20.0)
Drug–drug interactions	1 (6.7)
Death (not related to DTG)	1 (6.7)
Data not available	3 (20.0)

10 additional patients were lost to follow-up, and the rest continued with DTG 2DR. 2DR, 2-drug regimen; ARV, antiretroviral; DTG, dolutegravir; SD, standard deviation.